Axsome Therapeutics Prior to Significant Market Launches and FDA Approvals – Wells Fargo Sees 40% Chance!

Axsome Therapeutics (AXSM) aims to reach over 150 million people in the USA with treatment solutions for central nervous system (CNS) disorders and has the potential to achieve a peak revenue of $16.5 billion with its approved products and a promising pipeline. Currently, the antidepressant Auvelity, with a growth rate of 80% and accounting for over 79% of total revenues in Q1, is the key growth driver. CEO Herriot Tabuteau recently highlighted significant progress in the late-stage wide pipeline. Auvelity could receive FDA approval expansion with...